北京诺宁生物科技

Beijing Nuoning Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative gene therapies and high-efficiency viral vector manufacturing platforms. The company leverages its proprietary Nuon-AAV platform to optimize vector design and large-scale GMP production, aiming to improve the safety and accessibility of genetic medicines. Nuoning Bio's research pipeline primarily targets rare diseases, ophthalmology, and central nervous system disorders, with its lead candidate NN-101 currently in the IND stage for Leber hereditary optic neuropathy. Based in Beijing, the firm integrates advanced capsid engineering with internal manufacturing capabilities to accelerate the translation of gene therapies from the lab to the clinic. The company is backed by prominent venture capital firms and is positioned as a significant player in the Chinese cell and gene therapy landscape.